Titan Pharmaceuticals Stock

TTNP

US8883147055

Market Closed - Nasdaq Other stock markets 00:30:00 15/07/2026 +04			5-day change	1st Jan Change
0.8000 ^USD	+5.86%		+0.45%	-82.65%

04/10/25	Titan Pharmaceuticals announces closing of merger with Black Titan Corporation	RE
02/10/25	Titan Pharmaceuticals, Inc. Appoints Chay Weei Jye as the Sole Director and Acting Secretary, Effective October 1, 2025	CI

Valuation: Titan Pharmaceuticals

Market Cap	6.13M 5.37M 4.96M 4.58M 8.62M 590M 8.79M 59.23M 23.2M 288M 23.03M 22.52M 995M	P/E 2023	-1.11x	P/E 2024	-0.62x
Enterprise Value	3.3M 2.89M 2.67M 2.47M 4.64M 318M 4.73M 31.89M 12.49M 155M 12.4M 12.13M 535M	EV / Sales 2023	0.11x	EV / Sales 2024	-
Free-Float	-	Yield 2023 *	-	Yield 2024	-

* Estimated data More valuation ratios

Latest news : Titan Pharmaceuticals

04/10/25	Titan Pharmaceuticals announces closing of merger with Black Titan Corporation	RE
02/10/25	Titan Pharmaceuticals, Inc. Appoints Chay Weei Jye as the Sole Director and Acting Secretary, Effective October 1, 2025	CI
01/10/25	Titan Pharmaceuticals, Inc.(NasdaqCM:TTNP) dropped from NASDAQ Composite Index	CI
01/10/25	Ke Sdn. Bhd. completed the acquisition of Titan Pharmaceuticals, Inc. in a reverse merger transaction.	CI
15/08/25	Titan Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
27/06/25	Titan Pharmaceuticals, Inc. announced that it has received $0.6 million in funding from Blue Harbour Asset Management L.L.C	CI
24/06/25	Titan Pharmaceuticals, Inc. announced that it expects to receive $0.6 million in funding from Blue Harbour Asset Management L.L.C	CI
15/05/25	Titan Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
12/04/25	Titan Pharmaceuticals Announces $1 Million Private Placement Of Convertible Preferred Stock	RE
11/04/25	Titan Pharmaceuticals, Inc. announced that it has received $1 million in funding	CI
02/04/25	Titan Pharmaceuticals, Inc. Appoints Gabriel Loh as an Independent Director and Member of the Audit Committee	CI
29/03/25	Titan Pharmaceuticals, Inc. announced that it expects to receive $1 million in funding	CI
21/03/25	Titan Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI

More news

Analysts' recommendations: Titan Pharmaceuticals

26/05/22	Maxim Downgrades Titan Pharmaceuticals to Hold From Buy	MT
18/02/21	TITAN PHARMACEUTICALS : Maxim Group Upgrades Titan Pharmaceuticals to Buy From Hold, $11 Price Target	MT

More recommendations

Press Releases: Titan Pharmaceuticals

15/08/25	Titan Pharmaceuticals: Q2 Earnings Snapshot	AQ
06/08/25	TITAN PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Titan Pharmaceuticals, Inc. - TTNP	BU
28/06/25	Titan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock	AQ
03/06/25	Titan Pharmaceuticals Announces Filing of Registration Statement for Proposed Business Combination with TalenTec Sdn. Bhd.	AQ
15/05/25	Titan Pharmaceuticals: Q1 Earnings Snapshot	AQ

More press releases

Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.

Employees

Sector

More about the company

Quotes

Date	Price	Change	Volume
14/07/26	$0.8000	+5.86%	358,430
13/07/26	$0.7557	-0.88%	13,510
10/07/26	$0.7624	-5.01%	15,057
09/07/26	$0.8026	-0.06%	13,629
08/07/26	$0.8031	+6.09%	44,934

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

1 year	0.79	5.35
3 years	0	14.8
5 years	0	47.6
10 years	0	23,040.03

	2023	2024
Net sales	184K 161K 149K 137K 259K 17.7M 264K 1.78M 696K 8.65M 691K 676K 29.84M	-
Net income	-5.57M -4.88M -4.51M -4.16M -7.83M -536M -7.99M -53.79M -21.07M -262M -20.92M -20.45M -903M	-4.71M -4.12M -3.81M -3.51M -6.62M -453M -6.75M -45.45M -17.8M -221M -17.68M -17.28M -763M
Net Debt	-6.2M -5.42M -5.01M -4.63M -8.71M -596M -8.88M -59.84M -23.43M -291M -23.27M -22.75M -1B	-2.83M -2.48M -2.29M -2.11M -3.98M -272M -4.06M -27.34M -10.71M -133M -10.63M -10.4M -459M

Titan Pharmaceuticals Stock

Stocks

TTNP

US8883147055

Valuation: Titan Pharmaceuticals

Chart: Titan Pharmaceuticals

Latest news : Titan Pharmaceuticals

Analysts' recommendations: Titan Pharmaceuticals

Press Releases: Titan Pharmaceuticals

Quotes and Performance

Course Extremes

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	+5.86%
Current month	-82.65%
Current year	-82.65%